Vitestro Raises €12 Million in Series A Funding

Vitestro has completed a €12 million Series A financing round led by California-based Sonder Capital with participation from existing and new private investors experienced in the clinical lab and medtech sectors. 
 
The proceeds will be used to accelerate product development, prepare EU market authorization, and initiate production of the company’s autonomous blood drawing device. “This financing round marks a new phase of growth for Vitestro which brings the company closer to its mission of improving the venipuncture procedure for hundreds of millions of patients per year,” Vitestro Co-Founder/CEO Toon Overbeeke said. “We look forward to growing the business and transforming patient care with Sonder Capital, leveraging their expertise in successfully commercializing medical robotic technologies.”
 
Dr. Fred Moll, managing partner of Sonder Capital, has been appointed as non-executive board member at Vitestro. Moll has been called ‘the father of medical robotics’ after successfully co-founding Intuitive Surgical Inc., Hansen Medical, Restoration Robotics, and Auris Health (acquired by Johnson & Johnson).

“Medical robotics will make optimal outcomes available to everyone. I strongly believe Vitestro will set the world standard in autonomous blood drawing,” Moll stated.
 
Blood drawing is performed billions of times annually worldwide. It holds a pivotal role in clinical diagnostics yet is impacted by shortage of skilled healthcare workers. ”Automating this ubiquitous procedure is the next evolution for clinical laboratories, allowing them to improve quality of care for patients while building a more sustainable operation,” Sonder Capital Managing Partner Andy McGibbon noted.
 
Vitestro’s device combines artificial intelligence-based, ultrasound-guided 3D reconstruction with robotic needle insertion, ensuring accurate and secure blood collection. A prototype has been tested on more than 1,000 patients. Clinical studies will continue this year, with European market introduction anticipated in 2024. 
 
“Sonder Capital has a track record of creating lasting value for patients and hospitals. Vitestro’s long-term commitment to its customers will be supported by this partnership,” Vitestro Co-Founder/Commercial Director Brian Joseph said. 
 
In 2017 Vitestro’s founders rose to the challenge to create a better blood drawing experience. Today Vitestro is well underway to achieve its goal with a committed team of around 50 highly skilled people with a track record in medical robotics, imaging software, AI, QA/RA and business development. Vitestro is based in Utrecht, The Netherlands. 
 
Sonder Capital, based in Silicon Valley (California), invests time, capital and expertise in early stage medical technology companies. The Sonder Capital team includes veterans of the medical technology field, with decades of experience as founders, operators and investors. Sonder Capital takes a craftsman-like approach to helping innovators positively impact healthcare systems worldwide. Collectively, they are responsible for creating many notable public and private companies that have positively impacted millions of patients globally.